Phase 2 Esophageal Squamous Cell Carcinoma (ESCC) Clinical Trials
13 recruitingPhase 2
What is a Phase 2 trial?
Phase 2 trials evaluate whether a treatment works for a specific condition and further assess its safety. These studies typically enroll several hundred participants and provide preliminary data on effectiveness.
Showing 1–13 of 13 trials
Recruiting
Phase 2
Adebrelimab Combined With Neoadjuvant Chemotherapy in Borderline Resectable Locally Advanced Esophageal Squamous Cell Carcinoma
Esophageal Squamous Cell Carcinoma (ESCC)
Sun Yat-sen University42 enrolled1 locationNCT07638436
Recruiting
Phase 2
Phase II Study Evaluating Safety and Efficacy of Tislelizumab for Elderly Patients Unfit for Chemotherapy, With Advanced Esophageal Squamous-cell Carcinoma
Esophageal Squamous Cell Carcinoma (ESCC)
University Hospital, Clermont-Ferrand95 enrolled30 locationsNCT07205731
Recruiting
Phase 2
Adebrelimab Combined With Neoadjuvant Chemoradiotherapy for Esophageal Squamous Cell Carcinoma
Esophageal Squamous Cell Carcinoma (ESCC)
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University37 enrolled1 locationNCT07595770
Recruiting
Phase 2
Induction Chemo-Immunotherapy + Radiotherapy vs Concurrent Chemoradiotherapy for Unresectable Locally Advanced Esophageal Squamous Cell Carcinoma
Esophageal Squamous Cell Carcinoma (ESCC)
Second Affiliated Hospital of Zunyi Medical University92 enrolled1 locationNCT07559045
Recruiting
Phase 1Phase 2
177Lu-BetaBart in Patients With Relapsed/Refractory, Locally Advanced Inoperable, or Metastatic Solid Tumors
Colorectal, CancerOvarian CancerCervical Cancer+7 more
Radiopharm Theranostics, Ltd61 enrolled4 locationsNCT07189871
Recruiting
Phase 2
KC1036 in Combination With PD-1 Antibody and Platinum-based Chemotherapy for First-line Advanced Esophageal Cancer
Esophageal Squamous Cell Carcinoma (ESCC)
Beijing Konruns Pharmaceutical Co., Ltd.60 enrolled1 locationNCT07481058
Recruiting
Phase 2
Study of Tislelizumab Combined With Chemoradiotherapy and Surgery for Unresectable Esophageal Squamous Cell Carcinoma
Esophageal Squamous Cell Carcinoma (ESCC)Locally Advanced Unresectable Esophageal Cancer
Ming-Yu Lien45 enrolled8 locationsNCT07039162
Recruiting
Phase 2
The Efficacy and Safety of Iparomlimab and Tuvonralimab Injection Combined With Chemotherapy as the First-line Treatment for Esophageal Squamous Cell Carcinoma
Esophageal Squamous Cell Carcinoma (ESCC)
Hebei Medical University Fourth Hospital25 enrolled1 locationNCT07290010
Recruiting
Phase 2
Hypofractionated vs. Conventional Chemoradiotherapy After Induction Chemo-immunotherapy for Unresectable Esophageal Squamous Cell Carcinoma
Esophageal Squamous Cell Carcinoma (ESCC)
Sun Yat-sen University134 enrolled1 locationNCT06912074
Recruiting
Phase 1Phase 2
A Study to Investigate the Safety, Pharmacokinetics, and Clinical Activity of AP203 in Patients with Locally Advanced or Metastatic Solid Tumors, and Expansion to Selected Malignancies
Head and Neck Squamous Cell Carcinoma (HNSCC)Non-small Cell Lung Cancer (NSCLC)Locally Advanced or Metastatic Solid Tumors+1 more
AP Biosciences Inc.168 enrolled1 locationNCT05473156
Recruiting
Phase 2
Low-Dose Involved-Field Radiotherapy Plus Immunochemotherapy for ESCC
ImmunotherapyEsophageal Squamous Cell Carcinoma (ESCC)
Sichuan University41 enrolled1 locationNCT06603402
Recruiting
Phase 2
A Phase II Clinical Study of Sintilimab Combined with Chemotherapy Followed by Concurrent Chemoradiotherapy for Locally Advanced Unresectable Esophageal Squamous Cell Carcinoma (ESCC) (NICE-CS)
Esophageal Squamous Cell Carcinoma (ESCC)
Shanghai Chest Hospital52 enrolled1 locationNCT06709417
Recruiting
Phase 2
Neoantigen Vaccines in Esophageal Squamous Cell Carcinoma
Esophageal Squamous Cell Carcinoma (ESCC)Neoantigen-loaded Dendritic Cell VaccineImmune Checkpoint Inhibitors (ICIs)
Sichuan University165 enrolled1 locationNCT06675201